EPHA1 and hematopoietic and lymphoid cell neoplasm: Moreover, the use of monoclonal antibodies against Eph family receptors has gained attention as an effective therapeutic strategy in hematological tumors, emphasizing the significance of targeted therapies in addressing resistance and improving outcomes [126].